Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05294328 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia
A Phase 2 study of Presbyopia and Eye Diseases, sponsored by LENZ Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
- 5
- Study locations
NCT05294328: Completed Phase 2 study of Presbyopia and Eye Diseases, sponsored by LENZ Therapeutics.
NCT05294328 is a Phase 2 study of Presbyopia and Eye Diseases that has completed, run by LENZ Therapeutics. The registered enrollment target is 68 participants, below the 269-participant average among 38 other Presbyopia trials with a reported enrollment target (75% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05294328, a Phase 2 study of Presbyopia and Eye Diseases, has completed, sponsored by LENZ Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
- 5
- Study locations
Study Summary
To evaluate the safety and effectiveness of Aceclidine/Brimonidine (LNZ101) compared with Aceclidine (LNZ100) and vehicle in the treatment of Presbyopia.
Primary Outcome
Percentage of participants with at least a 3-line improvement in near vision and no loss ≥ 5 letters distance vision
Conditions Studied
Interventions
- DRUG Aceclidine+Brimonidine combination ophthalmic solution
- DRUG Aceclidine ophthalmic solution
- DRUG Vehicle Proprietary Ophthalmic Solution
Study Locations (5)
California
- INSIGHT-1 Study Site #4 - Glendale
Indiana
- INSIGHT-1 Study Site #3 - Indianapolis
Massachusetts
- INSIGHT-1 Study Site #1 - Andover
Tennessee
- INSIGHT-1 Study Site #2 - Memphis
Texas
- INSIGHT-1 Study Site #5 - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2022-05-05 |
| Est. Completion | 2022-09-10 |
| Phase | Phase 2 |
What the finished NCT05294328 record still lists
NCT05294328 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, below the 269-participant average among 38 other Presbyopia trials with a reported enrollment target (75% lower).
The record links to 3 conditions, with Presbyopia appearing as the primary indexed condition, and to 3 interventions - of which Aceclidine+Brimonidine combination ophthalmic solution is the first listed.
NCT05294328 lists 5 locations in 5 states (California, Indiana, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT05294328 about?
NCT05294328 is a clinical study titled "Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia". To evaluate the safety and effectiveness of Aceclidine/Brimonidine (LNZ101) compared with Aceclidine (LNZ100) and vehicle in the treatment of Presbyopia.
What is the current status of trial NCT05294328?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2022-05-05. Estimated completion is 2022-09-10.
What conditions does trial NCT05294328 study?
This clinical trial studies the following conditions: Presbyopia, Eye Diseases, Refractive Errors.
What interventions are being tested in trial NCT05294328?
The interventions under investigation include: Aceclidine+Brimonidine combination ophthalmic solution (DRUG), Aceclidine ophthalmic solution (DRUG), Vehicle Proprietary Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT05294328?
This trial is sponsored by LENZ Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05294328 being conducted?
This trial has 5 study locations across California, Indiana, Massachusetts, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Presbyopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05294328's enrollment target sits among peer trials
68 23rd of 38 higher than 16 of 38 other Presbyopia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Presbyopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Safety and Efficacy of UNR844 Chloride (UNR844-Cl) Eye Drops in Subjects With Presbyopia.
COMPLETED · Phase 2
-
Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia
COMPLETED · Phase 2
-
Post Market Clinical Evaluation of Clareon PanOptix Pro and Clareon PanOptix Pro Toric IOLs
RECRUITING · NA
-
A Clinical Comparison of Proclear® 1 Day Multifocal and Clariti® 1 Day Multifocal 3 Add
RECRUITING · NA
-
Comfort and Vision With TOTAL30 Multifocal Lenses
RECRUITING
-
North American Comfilcon A Clinical Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI